Shots:

• The P-III ORIENT-31 study evaluates sintilimab with/out Byvasda + CT vs CT in a ratio (1:1:1) in patients with EGFR-mutated LA or metastatic nonsq. NSCLC who have progressed following EGFR TKI treatment
• The study has met its prespecified 1EPs of PFS at 1st interim analysis. In the ITT population- sintilimab + Byvasda & CT showed an improvement in PFS & Sintilimab + CT also showed PFS benefit over CT alone- the safety profile was consistent with that observed in previously reported studies of sintilimab & Byvasda & no additional safety signals were observed
• Additionally- the regulatory submission is currently under review in China for sintilimab as 1L treatment of ESCC

  | Ref: PR Newswire | Image:Innovent